NCT05489224 - A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

471

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

June 29, 2023

Study Completion Date

November 23, 2023

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

CT-P47

CT-P47, 8 mg/kg (not exceeding 800 mg/dose) by intravenous (IV) infusion every 4 weeks (Q4W)

BIOLOGICAL

EU-approved RoActemra

EU-approved RoActemra, 8 mg/kg (not exceeding 800 mg/dose) by IV infusion Q4W

Trial Locations (1)

INTER CLINIC Piotr Adrian Klimiuk, Bialystok